An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Rogaratinib (Primary)
- Indications Adenocarcinoma; Bladder cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 15 Feb 2020 Results (n=74) assessing rogaratinib in expansion cohort in patients with advanced urothelial cancer presented at the 2020 Genitourinary Cancers Symposium
- 21 Jan 2020 Status changed from active, no longer recruiting to completed.
- 22 Dec 2019 Planned End Date changed from 27 Dec 2019 to 9 Jan 2020.